Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi, Mark S. Talamonti, Andrea Chiricozzi, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 1, pp. 235-252
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Clinical Benefits of Basic Emollient Therapy for the Management of Patients With Xerosis Cutis
Christian Vestergaard, Antonio Torrelo, Stéphanie Christen‐Zaech
International Journal of Dermatology (2025)
Open Access | Times Cited: 1
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
Francesco Bellinato, Paolo Gisondi, Giampiero Girolomoni
Biologics (2021) Vol. Volume 15, pp. 247-253
Open Access | Times Cited: 48
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease
Alfonso Motolese, Manuela Ceccarelli, Laura Macca, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 228-228
Open Access | Times Cited: 29
Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients
Luca Mastorino, Sara Susca, Caterina Cariti, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 9, pp. 1848-1853
Open Access | Times Cited: 22
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment
Luca Mastorino, Paolo Dapavo, Sara Susca, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2023) Vol. 22, Iss. 1, pp. 34-42
Open Access | Times Cited: 21
Psoriasis and skin cancer – Is there a link?
A. C. Balda, Irshad Wani, Tamsheel Fatima Roohi, et al.
International Immunopharmacology (2023) Vol. 121, pp. 110464-110464
Closed Access | Times Cited: 20
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps
Marco Caminati, Eugenio De Corso, Giancarlo Ottaviano, et al.
Current Allergy and Asthma Reports (2023) Vol. 24, Iss. 1, pp. 11-23
Open Access | Times Cited: 13
Therapies with Antioxidant Potential in Psoriasis, Vitiligo, and Lichen Planus
Fabrizio Guarneri, Lucrezia Bertino, Giovanni Pioggia, et al.
Antioxidants (2021) Vol. 10, Iss. 7, pp. 1087-1087
Open Access | Times Cited: 30
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice
Antonio Costanzo, Mar Llamas‐Velasco, Gabriella Fabbrocini, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 10, pp. 2004-2015
Open Access | Times Cited: 12
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
Matteo Megna, Cataldo Patruno, Maria Rita Bongiorno, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 5, pp. 2629-2633
Open Access | Times Cited: 17
Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years
Luca Mastorino, Paolo Dapavo, Lorenza Burzi, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 3, pp. 568-575
Open Access | Times Cited: 10
Psoriasis severity in moderate to severe psoriatic Greek patients routinely treated with systemic treatment: a cross-sectional and retrospective chart review study (CRYSTAL-Greece)
Dimitrios Rigopoulos, John Katsantonis, O. Neofotistou, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Therapeutic Strategies and Decision‐Making to Optimize Psoriasis Treatment: A French National Survey Based on Virtual Case Vignettes
N. Quiles‐Tsimaratos, N. Jouan, A. Vermersch‐Langlin, et al.
Dermatologic Therapy (2025) Vol. 2025, Iss. 1
Open Access
Active Switch From a Single Dose of Bimekizumab to Risankizumab in Psoriasis: A Pilot Study
Kaori Nakajima, Tomomitsu Miyagaki, Tatsuro Okano, et al.
The Journal of Dermatology (2025)
Closed Access
Effectiveness and Safety of Guselkumab in Patients With Moderate‐to‐Severe Plaque Psoriasis in Real‐World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance Study
Bong Seok Shin, Miri Kim, Moo Kyu Suh, et al.
The Journal of Dermatology (2025)
Open Access
Advancements in understanding and treating psoriasis: a comprehensive review of pathophysiology, diagnosis, and therapeutic approaches
Sai Chakith M. R., Sushma Pradeep, Manu Gangadhar, et al.
PeerJ (2025) Vol. 13, pp. e19325-e19325
Open Access
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In‐Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO‐4 Trial
Yukari Okubo, Akimichi Morita, Shinichi Imafuku, et al.
The Journal of Dermatology (2025)
Open Access
Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies
Salvatore Crisafulli, Lucrezia Bertino, Andrea Fontana, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 21
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Giampiero Girolomoni, L. Savage, Paolo Gisondi, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 10, pp. 2171-2185
Open Access | Times Cited: 8
Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis
Andrew Blauvelt, Melinda Gooderham, C.E.M. Griffiths, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 3, pp. 727-740
Open Access | Times Cited: 14
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
Matteo Megna, Cataldo Patruno, Maria Rita Bongiorno, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 6, pp. 525-531
Open Access | Times Cited: 13
Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
Akimichi Morita, Kiyohiro Nishikawa, Fumika Yamada, et al.
The Journal of Dermatology (2022) Vol. 49, Iss. 10, pp. 957-969
Open Access | Times Cited: 13
Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis
Ning Yu, Chen Peng, Jing Zhou, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 4, pp. 437-446
Closed Access | Times Cited: 7
Treat‐to‐target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis
Yael Renert‐Yuval, Ester Del Duca, B.W.M. Arents, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1, pp. 42-51
Open Access | Times Cited: 7
Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success
April W. Armstrong, Weily Soong, Jonathan A. Bernstein
Dermatology and Therapy (2023) Vol. 13, Iss. 8, pp. 1629-1646
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top